ArticleThe American journal of pathology2001
Caveolin-1 is down-regulated in human ovarian carcinoma and acts as a candidate tumor suppressor gene.
Article in The American journal of pathology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 117 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
117 citing papers in PubMed, 1 synthesis or guideline pooled it, 277 citations in OpenAlex.
- Pooled it
- Review
- Caveolin-1 mediates the utilization of extracellular proteins for survival in refractory gastric cancer.Experimental & molecular medicine · 2023Article
- PET and Optical Imaging of Caveolin-1 in Gastric Tumors.ACS omega · 2023Article
- The discovery of promising candidate biomarkers in kidney renal clear cell carcinoma: evidence from the in-depth analysis of high-throughput data.American journal of cancer research · 2023Article
- The Structural Proteins of Membrane Rafts, Caveolins and Flotillins, in Lung Cancer: More Than Just Scaffold Elements.International journal of medical sciences · 2023Review
- Article
- Identification and validation of a prognostic risk model based on caveolin family genes for breastFrontiers in cell and developmental biology · 2022Article
- The history of small extracellular vesicles and their implication in cancer drug resistance.Frontiers in oncology · 2022Review
- Quantitative proteomics identifies biomarkers to distinguish pulmonary from head and neck squamous cell carcinomas by immunohistochemistry.The journal of pathology. Clinical research · 2022Article
- Involvement of caveolin-1 in skin diseases.Frontiers in immunology · 2022Review
- Computational Methods for Prediction of Human Protein-Phenotype Associations: A Review.Phenomics (Cham, Switzerland) · 2021Review
- Increased ERK phosphorylation and caveolin-1 expression on K562 human chronic myelogenous leukemia cells by jacalin, a dietary plant lectin.Glycoconjugate journal · 2021Article
- Decreased HLF Expression Predicts Poor Survival in Lung Adenocarcinoma.Medical science monitor : international medical journal of experimental and clinical research · 2021Article
- PRER: A patient representation with pairwise relative expression of proteins on biological networks.PLoS computational biology · 2021Article
- Article
- Cyclodextrin nanosponge for the GSH-mediated delivery of Resveratrol in human cancer cells.Nanotheranostics · 2021Article
- Caveolin-1 Expression at Metastatic Lymph Nodes Predicts Unfavorable Outcome in Patients with Oral Squamous Cell Carcinoma.Pathology oncology research : POR · 2020Article
- Caveolin-1 suppresses tumor formation through the inhibition of the unfolded protein response.Cell death & disease · 2020Article
- Caveolin-1 Expression Together with VEGF can be a Predictor for Lung Metastasis and Poor Prognosis in Osteosarcoma.Pathology oncology research : POR · 2020Article
57 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To identify novel markers differentially expressed in ovarian cancer versus normal ovary, we hybridized microarrays with cDNAs derived from normal human ovaries and advanced stage ovarian carcinomas. This analysis revealed down-regulation of the caveolin-1 gene (CAV1) in ovarian carcinoma samples. Suppression of CAV1 in ovarian carcinomas was confirmed using a tumor tissue array consisting of 68 cDNA pools from different matched human tumor and normal tissues. Immunohistochemistry demonstrated expression of caveolin-1 in normal and benign ovarian epithelial cells, but loss of expression in serous ovarian carcinomas. In low-grade carcinomas, redistribution of caveolin-1 from a membrane-associated pattern observed in normal epithelium to a cytoplasmic localization pattern was observed. No expression of caveolin-1 was detectable in four of six ovarian carcinoma cell lines investigated. In SKOV-3 and ES-2 carcinoma cells, which express high levels of the caveolin-1 protein, phosphorylation of the 22-kd caveolin-1 isoform was detected. Inhibition of both DNA methylation and histone deacetylation using 5-aza-2'deoxycytidine and Trichostatin A, respectively, relieves down-regulation of caveolin-1 in OAW42 and OVCAR-3 cells which is in part mediated by direct regulation at the mRNA level. Expression of CAV1 in the ovarian carcinoma cell line OVCAR-3, resulted in suppression of tumor cell survival in vitro, suggesting that the CAV1 gene is likely to act as a tumor suppressor gene in human ovarian epithelium.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.